A 5-aminosalicylic acid (5-ASA) drug switch program switching from 5-ASA to sulfasalazine was instituted for insured patients with ulcerative colitis. Unanticipated barriers limited the number of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback